FVIIa antagonists
AssigneeGenentech, Inc.
InventorsMark S. Dennis, Charles Eigenbrot, Robert A. Lazarus
Life of this patent
Estimating the term…
Abstract
This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
Claims44
A compound which competes with SEQ ID NO:
- 1 for binding FVIIa in an in vitro assay.
Dependencies are inferred from the claim text.